Penicillin G Sodium for Injection Rx
Generic Name and Formulations:
Penicillin G sodium 5million Units/mL; pwd for IM inj or continuous IV drip after reconstitution; contains sodium 1.68mEq per million Units.
Indications for Penicillin G Sodium for Injection:
Susceptible severe infections where rapid and high penicillin levels are required (see literature).
Adults and Children:
Bacteremia, pneumonia, endocarditis, pericarditis, empyema, meningitis, other severe infections (due to streptococci, pneumococci, staphylococci): minimum of 5million Units per day. Syphilis: dosage and duration determined by age of patient and stage of disease. Gonorrheal endocarditis and arthritis: minimum 5million Units per day. Meningococcal meningitis: 1–2million Units IM every 2 hours, or continuous IV drip of 20–30million Units/day. Actinomycosis: 1–6million Units/day for cervicofacial cases; 10–20million Units/day for thoracic and abdominal disease. Clostridial infections: 20million Units/day as adjunctive therapy to antitoxin. Fusospirochetal infections: 5–10million Units/day. Rat-bite fever: 12–15million Units/day for 3–4 weeks. Listeria infections: Neonates: 500,000–1million Units/day. Adults with meningitis: 15–20million Units/day for 2 weeks. Adults with endocarditis: 15–20million Units/day for 4 weeks. Pasteurella infections: Bacteremia and meningitis: 4–6million Units/day for 2 weeks. Ersipeloid endocarditis: 2–20million Units/day for 4–6 weeks. Gram-negative bacteremia: 20–80million Units/day. Diphtheria (carrier state): 300,000–400,000 Units/day in divided doses for 10–12 days. Anthrax: a minimum of 5million Units/day in divided doses until cure is effected.
Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Electrolyte imbalance possible with rapid IV infusion; infuse slowly and monitor electrolytes frequently. Sodium-restricted. Monitor renal, hepatic and hematopoietic function with long-term therapy. Newborns. Infants. Pregnancy (Cat.B). Nursing mothers.
Bacteriostatic antibiotics (eg, erythromycin, tetracycline) may diminish bactericidal effects. Potentiated by probenecid. May cause positive Coombs test, false positive reactions to Clinitest, Benedict's solution or Fehling's solution.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|